2023年7月1日

阿爾菲健康——這是現在一個新的虛擬臨床肥胖患者——宣布210萬美元的資金由Y Combinator和尼娜資本連同Goodwater資本,鳳凰投資俱樂部,各種天使包括獨角獸Opentrons的創始人。+也宣布結果通過一個300人的病人平均在9個月失去了自身體重的10%到15%——類似於處方藥的結果稱為GLP-1類抗肥胖藥物(如Ozempic Wegovy Mounjaro,等等)——堅持阿爾菲健康的整體方法。現在有42%的美國人在肥胖、醫生和病人一直在尋找一個可持續的方法來減肥。目前,GLP-1類變得非常流行,損失10%到15%的平均體重。但這些藥物可以有重大的問題和缺點。創建輸入從肥胖專家從總體質量和克利夫蘭診所,專有ObesityRx係統利用人工智能進行代謝的病人理解為什麼他們獲得和保持體重。和係統使精密醫學建議(GLP-1s通常不是主要的藥物),以及建議的行為變化。Alfle的專家團隊和教練提供持續的遠程醫療支持。綜述了所有治療建議阿爾菲的醫療隊。阿爾菲健康是現在使用大型心髒病集團管理減肥的肥胖患者。 And they have also partnered with a large enterprise client referring appropriate patients to Alfie. The Alfie Health program is covered by major health insurance providers in select states. In order to determine a patient’s personalized metabolic profile and recommended weight loss treatment, Alfie Health’s ObesityRx clinical decision support solution leverages advanced AI algorithms to review a patient’s medical history; lab data; vitals via remote monitoring and patient-reported outcomes (PROs) that address satiety, satiation, and other aspects of metabolism. This platform makes an initial treatment recommendation for each patient based on their unique metabolic profile. And the analysis includes lifestyle change (nutrition, exercise, sleep, etc.) and medications alone or in combination when appropriate such as phentermine, topiramate, naltrexone, bupropion, metformin, and more—in addition to GLP-1s. The well-publicized GLP-1 medications are in short supply and hard to procure, are very expensive, costing as high as $1,000 a month (depending on insurance coverage, which is limited for most), and patients may have difficulty tolerating them over time. Importantly, certain patients may not lose significant weight while taking GLP-1s as these medications may not address the specific underlying metabolic dysfunction other medications might treat more effectively. In order to provide ongoing support, the Alfie program also includes monthly telehealth visits with specially trained providers and updated analyses driven by the ObesityRx platform. And patients meet virtually with health coaches to discuss progress, challenges, and strategies every two weeks. KEY QUOTES: “The results of our internal study are promising. Our patients have been struggling with obesity for years, or decades in some cases, and frequently suffer from other related health problems. ObesityRx technology provides a unique, data-driven approach that optimizes treatment strategies, streamlining costs associated with obesity and ensuring we strike the perfect balance in prescribing medications. It helps our clinicians determine the root cause of a patient’s obesity and utilize the most effective method from the get-go, which in many cases, may not include one of the GLP-1 medications.” — Alexander Singh, co-founder and CEO, Alfie Health “Our goal is to bring clinical-grade obesity management to patients at scale, something which has been extremely difficult to do, since there aren’t enough fellowship-trained obesity specialists for the over 130 million Americans struggling with obesity.” — Rohit Rustagi, Alfie Health co-founder and COO “Alfie Health brings a unique, comprehensive approach to treating obesity appropriately. The blend of interdisciplinary care teams, composed of physicians, advanced practice providers and health coaches in conjunction with Alfie Health’s novel technology allows them to provide personalized, virtual options in collaboration with patients’ regular medical specialists.” — Dr. W. Scott Butsch who is the Director of Obesity Medicine at the Cleveland Clinic’s Bariatric and Metabolic Institute and Alfie’s head clinical advisor Trending on Pulse 2.0